Paraoxonase-1 activity evaluation as a diagnostic and prognostic marker in horses and foals.
SIRS
acute phase protein
inflammation
oxidative stress
prognosis
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
25
09
2019
accepted:
23
01
2020
pubmed:
11
3
2020
medline:
15
12
2020
entrez:
11
3
2020
Statut:
ppublish
Résumé
In several species, paraoxonase-1 (PON-1) decreases during inflammation, because of the presence of oxidative stress; its measurement recently has been validated in horses, but its role as a clinical biomarker is unknown. To evaluate sensitivity, specificity and likelihood ratio of PON-1 activity to identify systemic inflammatory response syndrome (SIRS)-positive horses or horses with a poor prognosis. One hundred seventy-two blood samples from 58 sick horses from 3 different veterinary hospitals. In a cross-sectional study, PON-1 activity was measured upon admission and at 24-hour intervals until discharge or death, and results were analyzed based on SIRS status and outcome. No statistically significant difference was found in median PON-1 activity between SIRS and non-SIRS cases or between survivors and non-survivors except for mares, in which PON-1 activity was significantly lower in SIRS-positive horses (P = .05). The sensitivity of PON-1 activity in identifying horses with SIRS or negative outcome was low (0.0%-46.2% depending on the examined group) but its specificity was high (87.0%-100.0%). However, when PON-1 is low, the likelihood of death is 2.40-3.89 times higher than the likelihood of survival. Repeated measurement of PON-1 after treatment does not predict outcome. Evaluation of PON-1 activity in horses with inflammation might be advisable in the future, but only low activity at admission may be relevant in predicting SIRS or negative outcome.
Sections du résumé
BACKGROUND
BACKGROUND
In several species, paraoxonase-1 (PON-1) decreases during inflammation, because of the presence of oxidative stress; its measurement recently has been validated in horses, but its role as a clinical biomarker is unknown.
OBJECTIVES
OBJECTIVE
To evaluate sensitivity, specificity and likelihood ratio of PON-1 activity to identify systemic inflammatory response syndrome (SIRS)-positive horses or horses with a poor prognosis.
ANIMALS
METHODS
One hundred seventy-two blood samples from 58 sick horses from 3 different veterinary hospitals.
METHODS
METHODS
In a cross-sectional study, PON-1 activity was measured upon admission and at 24-hour intervals until discharge or death, and results were analyzed based on SIRS status and outcome.
RESULTS
RESULTS
No statistically significant difference was found in median PON-1 activity between SIRS and non-SIRS cases or between survivors and non-survivors except for mares, in which PON-1 activity was significantly lower in SIRS-positive horses (P = .05). The sensitivity of PON-1 activity in identifying horses with SIRS or negative outcome was low (0.0%-46.2% depending on the examined group) but its specificity was high (87.0%-100.0%). However, when PON-1 is low, the likelihood of death is 2.40-3.89 times higher than the likelihood of survival. Repeated measurement of PON-1 after treatment does not predict outcome.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Evaluation of PON-1 activity in horses with inflammation might be advisable in the future, but only low activity at admission may be relevant in predicting SIRS or negative outcome.
Identifiants
pubmed: 32154619
doi: 10.1111/jvim.15722
pmc: PMC7096640
doi:
Substances chimiques
Biomarkers
0
Aryldialkylphosphatase
EC 3.1.8.1
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
949-954Informations de copyright
© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Références
Vet J. 2013 Aug;197(2):499-501
pubmed: 23489842
Biochem Biophys Res Commun. 2004 Jun 4;318(3):680-3
pubmed: 15144891
Eur J Intern Med. 2017 Nov;45:46-50
pubmed: 28965741
Atherosclerosis. 1998 Aug;139(2):307-15
pubmed: 9712337
J Lipid Res. 2003 Apr;44(4):780-92
pubmed: 12562837
Clin Ter. 2014;165(1):e1-5
pubmed: 24589953
J Dairy Sci. 2007 Apr;90(4):1740-50
pubmed: 17369214
Domest Anim Endocrinol. 2012 Apr;42(3):129-41
pubmed: 22177629
J Vet Intern Med. 2017 Mar;31(2):582-592
pubmed: 28207163
Vet Clin Pathol. 2006 Mar;35(1):8-17
pubmed: 16511785
Vet Clin North Am Equine Pract. 2014 Aug;30(2):337-51, vii-viii
pubmed: 25016495
J Vet Intern Med. 2020 Mar;34(2):949-954
pubmed: 32154619
Scand J Immunol. 1998 Oct;48(4):419-24
pubmed: 9790313
Vet Clin Pathol. 2018 Mar;47(1):69-77
pubmed: 29575140
Clin Exp Med. 2010 Mar;10(1):21-5
pubmed: 19760042
Res Vet Sci. 2014 Oct;97(2):318-24
pubmed: 25104322
Vet Clin Pathol. 2013 Sep;42(3):329-41
pubmed: 23944371
Vet Immunol Immunopathol. 2015 Feb 15;163(3-4):210-5
pubmed: 25544632
Eur J Intern Med. 2018 Aug;54:1-5
pubmed: 29921471